Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

BofA analyst Allen Lutz estimates Hims & Hers’ year-over-year core revenue growth has “slowed sharply,” from about 45% in Q3 of 2024 to 29% in Q1 of 2025, despite a tailwind from shifting customers to ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) ...

Find insight on Novo Nordisk and more in the latest Market Talks covering the Health Care sector..